New drug combo shows promise in early breast cancer trial
NCT ID NCT01597388
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new experimental drug called AZD2014 combined with the standard hormone therapy fulvestrant in 99 people with advanced ER+ breast cancer. The main goals were to check the safety of the combination and find the right dose. Researchers also looked for early signs that the treatment might help shrink tumors or slow the cancer's growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AZD2014 (an experimental drug) and fulvestrant (a hormone therapy)
What this could lead to
If successful, this could lead to a new combination treatment option for people with advanced ER+ breast cancer that has stopped responding to standard hormone therapy.
What could go wrong
This is a very early Phase 1 trial with only 99 participants, focused mainly on safety and dosing. The drug may not prove effective enough to advance to larger studies, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED/METASTATIC BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Sarasota, Florida, 34232, United States
-
Research Site
Detroit, Michigan, 48201, United States
-
Research Site
Oklahoma City, Oklahoma, 73104, United States
-
Research Site
Greenville, South Carolina, 29605, United States
-
Research Site
Nashville, Tennessee, 37203, United States